Peter Blume-Jensen, President and CEO at Acrivon Therapeutics, Inc. (ACRV), bought 49,000 shares at $1.68 ($82K) on 2026-01-14, disclosed to the SEC on 2026-01-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |